DIRECTMX
LIVE

Serial Number

88614061

Owner

SALIPRO BIOTECH AB

Attorney

Timothy P. Naill

Filing Date

Sep 12, 2019

Add to watchlist:

No watchlists yet
View on USPTO

DIRECTMX Trademark

Serial Number: 88614061 • Registration: 6208690

DIRECTMX is a trademark filed by SALIPRO BIOTECH AB on September 12, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

SALIPRO BIOTECH AB (2 trademarks)

Stockholm SE-11428 , SE

Entity Type: 03

Trademark Details

Filing Date

September 12, 2019

Registration Date

December 1, 2020

Published for Opposition

September 15, 2020

Goods & Services

Biological laboratory services; Biochemistry consultancy; Consulting services in the field of lipid nanoparticles in particular in the field of lipid nanoparticles comprising protein or Saposin-lipid nanoparticles

Biological preparations for use in industry; Biological preparations for use in science; Carriers for biologically active compounds; Biological substances, materials, preparations and elements for scientific and industrial use in vivo and in vitro; Chemical substances, chemical materials and chemical preparations, and natural elements for scientific and industrial use in vivo and in vitro; biological materials for use in industry and science; Chemical substances, materials, preparations and elements for cosmetic preparations; Biological substances, materials, preparations and elements for cosmetic preparations; Lipid nanoparticles for use in industry and science; Lipid nanoparticles comprising protein for use in industry and science; Saposin-lipid nanoparticles for use in industry and science

Biochemical preparations for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases; Biochemical preparations for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases in non-human animals; Biological reagents for medical use; Biological reagents for veterinary use; Carriers for pharmaceutical, medical, veterinary or diagnostic compounds; Biochemical preparations for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases in humans and non-human animals and for use in a diagnostic method; Medicinal preparations and substances for preventing or treating infectious or parasitic diseases, cancer, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye, diseases of the ear, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system and autoimmune diseases in humans and non-human animals; Veterinary vaccines; Human vaccine preparations; Lipid nanoparticles for medicinal, diagnostic or pharmaceutical purposes; Lipid nanoparticles comprising protein for medical, diagnostic or pharmaceutical purposes; Saposin-lipid nanoparticles for medical, diagnostic or pharmaceutical purposes

Treatment of cells and/or viruses and/or biological membranes to obtain carriers for biologically active, pharmaceutical or diagnostic compounds; Conversion of cells and/or viruses and/or biological membranes into biochemical preparations; Custom manufacturing of lipid nanoparticles in particular of lipid nanoparticles comprising protein or Saposin-lipid nanoparticles; Processing of cells and/or viruses and/or biological membranes for third parties

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 1, 2025 REM1
REGISTERED-PRINCIPAL REGISTER
Dec 1, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 15, 2020 NPUB
PUBLISHED FOR OPPOSITION
Sep 15, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 9, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 9, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 9, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 9, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 9, 2020 CNEA
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 24, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 24, 2020 GNSL
SUSPENSION LETTER WRITTEN
Jun 24, 2020 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 15, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 15, 2020 CRFA
ASSIGNED TO LIE
Jun 15, 2020 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 4, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 19, 2019 GNRN
NON-FINAL ACTION E-MAILED
Dec 19, 2019 GNRT
NON-FINAL ACTION WRITTEN
Dec 19, 2019 CNRT
ASSIGNED TO EXAMINER
Dec 13, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 20, 2019 NWOS
NEW APPLICATION ENTERED
Sep 16, 2019 NWAP